Last update 13 Sep 2025

Anlotinib Dihydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ALTN, Anlotinib, Anlotinib Hydrochloride
+ [6]
Action
antagonists, inhibitors
Mechanism
FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), Tyrosine kinase inhibitors
Originator Organization
License Organization-
Drug Highest PhaseApproved
RegulationOrphan Drug (United States), Priority Review (China), Special Review Project (China), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H23ClFN3O3
InChIKeyGTAUHBAHFJIAQT-UHFFFAOYSA-N
CAS Registry1360460-82-7

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Renal Cell Carcinoma
China
13 May 2025
Unresectable Renal Cell Carcinoma
China
13 May 2025
Endometrial Carcinoma
China
22 Nov 2024
Extensive stage Small Cell Lung Cancer
China
08 May 2024
Differentiated Thyroid Gland Carcinoma
China
08 Apr 2022
Thyroid Cancer, Medullary
China
30 Jan 2021
Small Cell Lung Cancer
China
01 Sep 2019
Soft Tissue Sarcoma
China
01 Jul 2019
Non-Small Cell Lung Cancer
China
14 May 2018
Locally Advanced Lung Non-Small Cell Carcinoma
China
08 May 2018
metastatic non-small cell lung cancer
China
08 May 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alveolar Soft Part SarcomaNDA/BLA
China
23 Aug 2025
Advanced Lung Non-Small Cell Squamous CarcinomaNDA/BLA
China
23 Apr 2025
Non-small cell lung cancer stage IIINDA/BLA
China
23 Apr 2025
Hepatocellular CarcinomaNDA/BLA
China
21 Nov 2024
Metastatic Pancreatic Ductal AdenocarcinomaPhase 3
China
01 Oct 2025
Small cell lung cancer limited stagePhase 3
China
01 Sep 2024
Primary peritoneal carcinomaPhase 3
United States
06 Apr 2022
Primary peritoneal carcinomaPhase 3
United States
06 Apr 2022
Primary peritoneal carcinomaPhase 3
China
06 Apr 2022
Primary peritoneal carcinomaPhase 3
China
06 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Advanced Lung Non-Small Cell Carcinoma
First line
EGFR sensitive mutation (Ex19del, L858R),TP53 mutation
15
pitevwtzhr(ytlxtrvztq) = avevdsxuth pnnnyzgssd (kwqlkmwymv, 11.0 - NA)
Positive
09 Sep 2025
gagyfyogke(frbszaqzyw) = ilchwmoadm rprmegncux (evvamljazz )
Phase 2
Advanced Lung Non-Small Cell Carcinoma
First line
EGFR sensitive mutation (Ex19del, L858R)
16
Sunvozertinib+Anlotinib
erczvlkxga(uogakuwsnq) = fskitwxcqk xnemtfvpcn (grxmlypplr )
Positive
09 Sep 2025
Phase 1
Advanced Lung Non-Small Cell Carcinoma
Third line | Second line
KRAS mutation
12
trametinib+Anlotinib+Tislelizumab
zoeiblqvyx(ukvsbiyzvr) = ykxhltetvu amgrggetnz (uinrexhdzx )
Positive
08 Sep 2025
Phase 2
29
dutajreslb(topfihqref) = sizejohras fklfinxgyg (myfxknjfwm )
Positive
01 Sep 2025
Not Applicable
210
ntexqwdtau(qsxkpgcnql) = ewgtllzhxz zrphaeosdd (adarbrrkhq )
Positive
03 Jul 2025
(Other treatment methods not including anti-angiogenic TKIs)
ntexqwdtau(qsxkpgcnql) = ccspfjltzz zrphaeosdd (adarbrrkhq )
Not Applicable
Gastrointestinal Neoplasms
RGC32 | TGFβ1 pathway
256
Anlotinib monotherapy or combination group
hltphcihvd(xlqnsthbwj) = mjjvstetjw ekcoppozce (jvnvvkngah, 2.4 - 8.1)
Positive
03 Jul 2025
Other treatments without anti-angiogenic TKIs group
hltphcihvd(xlqnsthbwj) = rzxtxymidi ekcoppozce (jvnvvkngah, 2.8 - 4.8)
Phase 2
40
qqajxazmdx(awwagwrtag) = dnevayrobg iikdnvdsjl (ylbifphbos, 12.1 - NE)
Positive
01 Jul 2025
Not Applicable
-
Anlotinib + Camrelizumab + Chemotherapy (TCAC group)
jorjrqmfws(plggiidrzp) = wqjxfcqdld kancgpjlta (ejodaemjrr )
-
01 Jul 2025
Camrelizumab + Chemotherapy (TCC group)
jorjrqmfws(plggiidrzp) = fqhlmbrpyi kancgpjlta (ejodaemjrr )
Phase 2
Triple Negative Breast Cancer
Neoadjuvant
programmed death-ligand 1 (PD-L1)-negative
29
ljmacoqotf(grsbuuqqzb) = jrowtmwrvg dcrurbovwn (qnlcmhgynr, 49.0% - 85.0)
Positive
01 Jul 2025
Phase 2
37
qmznpbbmag(svfhqmfpot) = cguehefwal wmdkldfopg (qqvayustdo )
Positive
01 Jul 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free